Aerie Pharmaceuticals (NASDAQ:AERI) Given a $77.00 Price Target at Mizuho

Aerie Pharmaceuticals (NASDAQ:AERI) received a $77.00 price objective from Mizuho in a report released on Friday, TipRanks reports. The firm currently has a “buy” rating on the stock. Mizuho’s price target would suggest a potential upside of 259.98% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. JMP Securities set a $58.00 target price on shares of Aerie Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, July 2nd. Canaccord Genuity set a $56.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 11th. BidaskClub downgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. ValuEngine upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Needham & Company LLC reiterated a “positive” rating and issued a $74.00 target price on shares of Aerie Pharmaceuticals in a research report on Wednesday, July 10th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $69.50.

AERI stock traded up $0.13 during midday trading on Friday, reaching $21.39. The company had a trading volume of 25,363 shares, compared to its average volume of 892,590. Aerie Pharmaceuticals has a 1 year low of $20.88 and a 1 year high of $67.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.47 and a quick ratio of 3.27. The stock has a market capitalization of $1.00 billion, a P/E ratio of -4.59 and a beta of 0.41. The company’s 50 day moving average price is $25.96.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Tuesday, May 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.13. Aerie Pharmaceuticals had a negative net margin of 684.56% and a negative return on equity of 93.96%. The company had revenue of $10.85 million during the quarter, compared to the consensus estimate of $12.66 million. As a group, equities research analysts predict that Aerie Pharmaceuticals will post -2.97 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its holdings in shares of Aerie Pharmaceuticals by 13.6% during the 1st quarter. Jennison Associates LLC now owns 1,344,999 shares of the company’s stock valued at $63,887,000 after purchasing an additional 161,538 shares in the last quarter. FMR LLC raised its holdings in shares of Aerie Pharmaceuticals by 0.4% during the 4th quarter. FMR LLC now owns 978,953 shares of the company’s stock valued at $35,340,000 after purchasing an additional 3,950 shares in the last quarter. Pictet Asset Management Ltd. raised its holdings in shares of Aerie Pharmaceuticals by 42.2% during the 1st quarter. Pictet Asset Management Ltd. now owns 810,410 shares of the company’s stock valued at $38,494,000 after purchasing an additional 240,322 shares in the last quarter. Candriam Luxembourg S.C.A. raised its holdings in shares of Aerie Pharmaceuticals by 26.3% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 604,800 shares of the company’s stock valued at $28,729,000 after purchasing an additional 126,000 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in shares of Aerie Pharmaceuticals by 0.9% during the 2nd quarter. Rice Hall James & Associates LLC now owns 538,249 shares of the company’s stock valued at $15,905,000 after purchasing an additional 4,992 shares in the last quarter.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: When can a hold rating present a buying opportunity?

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.